Founder and COO and CTO @ (October 2019 - February 2025)
Head of Global Technology and Innovation, Biopharma Business Unit @ (October 2019 - January 2021)
Technology Innovation Manager @ (May 2017 - October 2019)
Assoc. Manager, Technology and Innovation @ (April 2015 - May 2017)
Process Scientist @ (October 2013 - April 2015)
Life Scientist: Applications Development @ (June 2012 - October 2013)
Founder and Business Development and Marketing @ (September 2010 - September 2011)
Research Fellow @ (September 2008 - June 2011)
Research Intern @ (March 2010 - June 2010)
Product Consultant @ (April 2008 - October 2008)
Samet Yildirim Education
Keck Graduate Institute
Masters (Biotechnology, Business)
2011-2013
Ankara University
Master Of Science (Biophysics)
2008-2010
Ankara University
Bachelor Of Science (Biology)
2003-2008
Samet Yildirim Skills
Biotechnology
Molecular Biology
R&D
Market Research
Cell Culture
Business Strategy
Biochemistry
Life Sciences
Research
Team Leadership
Innovation Management
Business Development
Management
Strategic Partnerships
Project Management
Product Management
Intrapreneurship
Commercialization
Product Innovation
Western Blotting
Data Analysis
Teamwork
Product Development
PCR
Team Management
Assay Development
Genetics
Protein Chemistry
qPCR
Corporate Finance
Integration
Customer Service
Program Management
See 10+see Less
Microsoft Excel
Marketing
Public Speaking
Samet Yildirim Summary
Samet Yildirim, based in San Francisco, CA, US, is currently a Co-Founder and Chief Business Officer at HexemBio. Samet Yildirim brings experience from previous roles at Keck Graduate Institute, Orbillion Bio [Acquired] and Boehringer Ingelheim. Samet Yildirim holds a 2011 - 2013 Masters in Biotechnology, Business @ Keck Graduate Institute. With a robust skill set that includes Biotechnology, Molecular Biology, R&D, Market Research, Cell Culture and more. Samet Yildirim has 3 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Samet Yildirim?
Find contact details for 700 million professionals.